TY  - JOUR
T1  - Ethnopharmacology in Combating Emerging Diseases: Lessons from COVID-19 in Nigeria 
AU  - Agbamu, Emmanuel
AU  - Balogun, Triumph
AU  - Okoro, Promise Kamsiyochukwu
AU  - Balogun, Kabeerat Arike
AU  - Ekpoboredefe, Justinah
AU  - Iteh, Nduka Godsgift
AU  - Ebulu, Christabel
JF  - Journal of Exploratory Research in Pharmacology
VL  - 11
IS  - 3
SN  - 2572-5505
SP  - e00004
EP  - e00004
Y1  - 2026-09-30
DO  - 10.14218/JERP.2026.00004
UR  - https://www.xiahepublishing.com/2572-5505/JERP-2026-00004
AB  - Emerging diseases are those that appear in a population for the first time or previously existed, but rapidly increase in incidence or geographic range. During the coronavirus disease 2019 (COVID-19) pandemic, ethnopharmacological practices became prominent in Nigeria because herbal remedies were affordable, locally accessible, and supported by longstanding cultural trust. However, despite broad public use and some regulatory progress, evidence for the safety, efficacy, standardization, and clinical application of these remedies remains limited. This narrative review examines the integration of ethnopharmacology into Nigeria’s COVID-19 response, evaluates its strengths, constraints, and lessons, and considers future pathways for incorporating ethnopharmacological practices into epidemic preparedness and response strategies. It reviews literature and regulatory information published from 2015 to 2025, focusing on herbal remedies used during the pandemic, regulatory listing processes, and key research gaps. Common remedies were derived from Zingiber officinale, Allium sativum, Citrus limon, Curcuma longa, and Garcinia kola. The National Agency for Food and Drug Administration and Control in Nigeria accelerated toxicological testing and listed 14 local herbal medicines, including Pax Herbal Cugzin, Niprimune, and IHP Detox Tea. This established a baseline safety for human consumption but did not validate therapeutic efficacy against severe acute respiratory syndrome coronavirus 2, which requires rigorous clinical trials. Although some formulations showed promising findings in preliminary clinical, in silico, and in vitro studies, the evidence was constrained by small pilot samples, absence of multiphase randomized controlled trials, insufficient in vivo pharmacokinetic data, and difficulties in isolating active compounds necessary for batch-to-batch consistency. Strengthening Nigeria’s resilience to future epidemics will require sustained investment in scientific research infrastructure, toxicogenomic and metabolomic studies, robust intellectual property frameworks for indigenous knowledge, and transparent public communication to reduce misinformation and product misuse.